---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-021481"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:41:10.868851+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept Q3 revenue $96.1M (+11% YoY); narrows 2021 guide to $365-375M

## Summary
- GAAP diluted EPS $0.24 vs $0.17 YoY; non-GAAP diluted EPS $0.30 vs $0.24.
- Cash and investments $495.2M, up from $471.6M at June 30; repurchased 1.2M shares in Q3.
- Plans Phase 3 trial in recurrent platinum-resistant ovarian cancer in Q1 2022; updated OS data expected Q1 2022.
- Phase 2 NASH data to be presented at AASLD Nov 12-15; Phase 1b dose-finding trial initiated.
- Relacorilant NDA submission for Cushing's syndrome expected Q2 2023; GRACE and GRADIENT trials enrolling.

## SEC filing metadata
- accession: 0001628280-21-021481
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828021021481/0001628280-21-021481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828021021481/cort-20211103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-021481
- JSON: https://secwatch.observer/filing/0001628280-21-021481.json
- Plain text: https://secwatch.observer/filing/0001628280-21-021481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.